121 related articles for article (PubMed ID: 37821774)
1. Discovery of a Dual-Target Inhibitor of CDK7 and HDAC1 That Induces Apoptosis and Inhibits Migration in Colorectal Cancer.
Chen Y; Zhang S; Li Z; Yin B; Liu Y; Zhang L
ChemMedChem; 2023 Dec; 18(23):e202300281. PubMed ID: 37821774
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.
Li Y; Luo X; Guo Q; Nie Y; Wang T; Zhang C; Huang Z; Wang X; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R
J Med Chem; 2018 Apr; 61(7):3166-3192. PubMed ID: 29518312
[TBL] [Abstract][Full Text] [Related]
3. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
4. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Kim SL; La MT; Shin MW; Kim SW; Kim HK
Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21
Zhou H; Cai Y; Liu D; Li M; Sha Y; Zhang W; Wang K; Gong J; Tang N; Huang A; Xia J
Cell Prolif; 2018 Jun; 51(3):e12447. PubMed ID: 29484736
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors.
Hu H; Chen F; Dong Y; Li M; Xu S; Qin M; Gong P
Eur J Med Chem; 2020 Oct; 204():112651. PubMed ID: 32738414
[TBL] [Abstract][Full Text] [Related]
7. Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.
Di Bello E; Sian V; Bontempi G; Zwergel C; Fioravanti R; Noce B; Castiello C; Tomassi S; Corinti D; Passeri D; Pellicciari R; Mercurio C; Varasi M; Altucci L; Tripodi M; Strippoli R; Nebbioso A; Valente S; Mai A
Eur J Med Chem; 2023 Feb; 247():115022. PubMed ID: 36549114
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Cheng C; Yun F; Ullah S; Yuan Q
Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
[TBL] [Abstract][Full Text] [Related]
9. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.
Lee HY; Tang DW; Liu CY; Cho EC
Chem Biol Interact; 2022 Jan; 352():109778. PubMed ID: 34929181
[TBL] [Abstract][Full Text] [Related]
10. Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth.
Duan N; Hu X; Qiu H; Zhou R; Li Y; Lu W; Zhu Y; Shen S; Wu W; Yang F; Liu N
Cell Death Dis; 2023 Dec; 14(12):801. PubMed ID: 38062013
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.
Duan Y; Yu T; Jin L; Zhang S; Shi X; Zhang Y; Zhou N; Xu Y; Lu W; Zhou H; Zhu H; Bai S; Hu K; Guan Y
Eur J Med Chem; 2023 Jun; 254():115367. PubMed ID: 37086699
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression.
Li R; Gan YH
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481295
[TBL] [Abstract][Full Text] [Related]
13. T-17, a novel cyclin-dependent kinases/histone deacetylases dual inhibitor, induces cancer cells death through cell cycle arrest and apoptosis.
Zhang L; Long R; Li X; Jiang J; Chen H; Tian B; Long B; Yu Y; Gan Z
Drug Dev Res; 2022 Nov; 83(7):1578-1588. PubMed ID: 35844039
[TBL] [Abstract][Full Text] [Related]
14. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
[TBL] [Abstract][Full Text] [Related]
16. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
17. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
18. Harmine-based dual inhibitors targeting histone deacetylase (HDAC) and DNA as a promising strategy for cancer therapy.
Lu D; Qu L; Wang C; Luo H; Li S; Yin F; Liu X; Chen X; Luo Z; Cui N; Peng W; Ji L; Kong L; Wang X
Bioorg Chem; 2022 Mar; 120():105604. PubMed ID: 35051708
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel polysubstituted
Wang Z; Zhao L; Zhang B; Feng J; Wang Y; Zhang B; Jin H; Ding L; Wang N; He S
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2206581. PubMed ID: 37144599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
